Blood pressure, Fluid Retention and the Cardiovascular Risk of Drugs

• Grossman E , MesserliFH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am. J. Med., 125, 14–22 (2012).
   PubMed Web of Science ®Google Scholar
• Novak KK . (Ed.). Drug Facts and Comparisons. Wolters Kluwer Health Inc., MO, USA (2011).
   Google Scholar
• Bombardier C , LanineL, ReicinAet al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. , 343, 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Nussmeier NA , WheltonAA, BrownMTet al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. , 1352, 1081–1091 (2005).
   Google Scholar
• McGettigan P , HenryD. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 296, 1633–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Juni P , NarteyL, ReichenbachS, SterchiR, DieppePA, EggerM. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 364, 2021–2029 (2004).
   PubMed Web of Science ®Google Scholar
• Antman EM , BennettJS, DoughertyA, FurbergC, RobertsH, TaubertKA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a statement from the American Heart Association. Circulation, 115, 1634–1642 (2007).
   PubMed Web of Science ®Google Scholar
• Barter PJ , CaulfieldM, ErikssonMet al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. , 357, 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Singh S , LokeYK, SpanglerJG, FurbergCD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ, 183, 1359–1366 (2011).
   PubMed Web of Science ®Google Scholar
• Ballard C , CorbettA. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs, 24, 729–739 (2010).
   PubMed Web of Science ®Google Scholar
• Seitz DP , AdunuriN, GillSS, GruneirA, HerrmannN, RochonP. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst. Rev., 2, CD008191 (2011).
   Google Scholar
• Salzman C , JesteDV, MeyerREet al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J. Clin. Psychiatry , 69, 889–898 (2008).
   PubMed Web of Science ®Google Scholar
• Lewington S , ClarkeR, QizilbashN, PetoR, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Weber MA . The ALLHAT report: a case of information and misinformation. J. Clin. Hypertens., 5, 9–13 (2003).
   Google Scholar
• Cooper WO , HabelLA, SoxCMet al. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. , 365, 1896–1904 (2011).
   PubMed Web of Science ®Google Scholar
• Habel LA , CooperWO, SoxCMet al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA , 306, 2673–2683 (2011).
   PubMed Web of Science ®Google Scholar
• Nissen SE , WolskiE. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular cause. N. Engl. J. Med., 356, 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Singh S , LokeYK, FurbergCD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA, 298, 1189–1195 (2007).
   PubMed Web of Science ®Google Scholar
• Pantalone KM , KattanMW, YuCet al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in Type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. , 46, 145–154 (2009).
   PubMed Web of Science ®Google Scholar
• Hsaio FY , HuangWF, WenYW, ChenPF, KuoKN, TsaiYW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf., 32, 675–690 (2009).
   PubMed Web of Science ®Google Scholar
• Basaria S , CovielloAD, TravisonTGet al. Adverse events associated with testosterone administration. N. Engl. J. Med. , 363, 109–122 (2010).
   PubMed Web of Science ®Google Scholar
• Johannsson G , GibneyJ, WolthersT, LeungKC, HoKK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J. Clin. Endrocrinol. Metab., 90, 3989–3994 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson SL , EicherA, PaulMS, GiraudGD, MortonMJ, ThornburgKL. The sequential effects of estrogen administration and hypertension on cardiac function in ewes. Am. J. Obstet. Gynecol., 179, 610–619 (1998).
   PubMed Web of Science ®Google Scholar
• Kamali P , MüllerxT, LangU, ClappJF 3rd. Cardiovascular responses of perimenopausal women to hormonal replacement therapy. Am. J. Obstet. Gynecol., 182, 17–22 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis MA , HeinemannLA, SpitzerWO, MacRaeKD, BruppacherR. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception, 56, 129–140 (1997).
   PubMed Web of Science ®Google Scholar
• Light KC , HinderliterAL, WestSGet al. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J. Hypertens. , 19, 269–278 (2001).
   PubMed Web of Science ®Google Scholar
• Lundh B , GardnerFH. The effect of testosterone in pharmacological doses on plasma volume and on some serum proteins in patients with sickle cell anemia and in sexually impotent men. Scand. J. Clin. Lab. Invest., 28, 72–78 (1971).
   PubMedGoogle Scholar
• Pelzer T , JazbutyteV, HuKet al. The estrogen receptor-alpha agonist 16α-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc. Res. , 67, 604–612 (2005).
   PubMed Web of Science ®Google Scholar
• Quan A , ChakravartyS, ChenJKet al. Androgens augment proximal tubule transport. Am. J. Physiol. Renal. Physiol. , 287, F452–F459 (2004).
   PubMed Web of Science ®Google Scholar
• Rossouw JE , AndersonGL, PrenticeRLet al.; Writing Group for the Women‘s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women‘s Health Initiative randomized controlled trial. JAMA, 288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Keating NL , O‘MalleyAJ, SmithMR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol., 24, 4448–4456 (2006).
   PubMed Web of Science ®Google Scholar
• Alibhai SM , Duong-HuaM, SutradharRet al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. , 27, 3452–3458 (2009).
   PubMed Web of Science ®Google Scholar
• Schramm TK , GislasonGH, VaagAet al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. , 32, 1900–1908 (2011).
   PubMed Web of Science ®Google Scholar
• Blankfield RP . Calculated effect of fluid retention upon velocity of blood flow and turbulence: implications for atherosclerosis. Clin. Hemorheol. Microcirc., 47, 79–86 (2011).
   PubMed Web of Science ®Google Scholar
• Funk CD , FitzGeraldGA. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol., 50, 470–479 (2007).
   PubMed Web of Science ®Google Scholar
• Yu Y , RicciottiE, GrosserT, FitzgeraldGA. The translational therapeutics of prostaglandin inhibition in atherothrombosis. J. Thromb. Haemost., 7(Suppl. 1), 222–226 (2009).
   PubMedGoogle Scholar
• Lincoff AM , WolskiK, NichollsSJ, NissenSE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus. JAMA, 298, 1180–1188 (2007).
   PubMed Web of Science ®Google Scholar
• Nagajothi N , AdigopulaS, BalamuthusamySet al. Pioglitazone and the risk of myocardial infarction and other adverse cardiac events: a meta-analysis of randomized, controlled trials. Am. J. Ther. , 15, 506–511 (2008).
   PubMed Web of Science ®Google Scholar

Website

• US FDA briefing materials saxagliptin. www.fda.gov/downloads/advisorycommittees/../ucm148101.pdf
   Google Scholar